Press Release

NEW YORK and LONDON,and FREISING, Germany, April 14, 2016 Akari Therapeutics (NASDAQ: AKTX), an emerging growth, development-stage biopharmaceutical company, …

[Read more...] about Akari Therapeutics Plc and XL-protein GmbH Sign License Agreement to Develop a Long Acting Version of Coversin Using PASylation® Technology

NEW YORK and LONDON, March 31, 2016 Akari Therapeutics (NASDAQ: AKTX), an emerging growth, development-stage biopharmaceutical company, announced today …

[Read more...] about Akari Therapeutics Announces Positive Preliminary Results from First PNH Patient Treated With Coversin

NEW YORK and LONDON, March 1, 2016 Akari Therapeutics (NASDAQ: AKTX), an emerging growth, development-stage biopharmaceutical company, announced today that …

[Read more...] about Akari Therapeutics to Present at Cowen and Company 36th Annual Health Care Conference

NEW YORK and LONDON, February 17, 2016 Akari Therapeutics (NASDAQ: AKTX), an emerging growth, development-stage biopharmaceutical company, announced today …

[Read more...] about Akari Therapeutics to Participate in the 2016 SunTrust Robinson Humphrey Orphan Drug Day

NEW YORK and LONDON, January 29, 2016 Akari Therapeutics (NASDAQ: AKTX), an emerging growth, development-stage biopharmaceutical company, announced today the …

[Read more...] about Akari Therapeutics Receives Approval from the UK Medicines & Healthcare Products Regulatory Agency for Phase IB Multiple Ascending Dose Trial